Oct 26 (Reuters) - Trinity Biotech PLC :Trinity biotech announces results for Q3, 2017.Q3 earnings per share $0.063.Q3 revenue $25.6 million versus I/B/E/S view $26.1 million.
Trinity Biotech Plc : Trinity biotech announces withdrawal of Troponin FDA 510(k) submission . FDA asked trinity to consider withdrawing their submission, due to some concerns they have about submission . To move technology from swedish facility to facility in ireland where it will be incorporated into research and development,manufacturing infrastructure . Moving of technology will result in closure of uppsala facility in sweden, which will result in approximately 40 redundancies . Trinity biotech announces withdrawal of troponin fda 510(k) submission . Held a meeting with fda on thursday 29 september, in order to obtain an update on company's meritas troponin submission . Fda asked trinity to consider withdrawing their submission, due to some concerns they have about submission . Fda's primary concerns relate to device's operating temperature range . "over coming weeks we will engage with fda to gain a better understanding of nature of their concerns" . Fda concerns also relate to troponin-i clinical performance not being consistent with clinical performance data .Will also recognise a non-cash write-off in excess of $50m, representing costs incurred on project, which will be recognised in q4.